Primary pleuropulmonary synovial sarcomas are rare soft tissue malignancies; combined metastatic involvement of the heart is extremely rare. In this case report, a 17-year-old female presented with a history of chest pain. Chest radiographs revealed a round mass in the left upper hemithorax, and computed tomography (CT) showed a well-defined heterogeneous enhancing mass abutting the pleura. A core needle biopsy revealed malignant spindle cells. Surgical resection was performed, and a final diagnosis of primary pleural synovial sarcoma, monophasic fibrous type, was made. The patient underwent radical irradiation and chemotherapy and remained stable for 28 months until a follow-up chest CT showed a poorly enhancing nodule in the left pericardial region that enlarged after 5 months. Surgical resection was performed. Histological examination confirmed metastatic cardiac involvement from a primary pleural synovial sarcoma. We report this unusual case of a primary pleural synovial sarcoma metastasis to the heart.
Introduction
Primary pleuropulmonary synovial sarcoma (PPSS) is a rare soft tissue malignancy representing only 0.1% -0.5% of all primary lung malignancies. It commonly arises from the chest wall, lung parenchyma, pleura or mediastinum. It is usually diagnosed during the fifth decade of life (1) . The frequency of cardiac metastasis from soft tissue sarcomas ranges from 3.5% to 35% with only two cases of metastatic synovial sarcoma of the heart reported: one involving the right ventricle and the other the left ventricle. Both cases had a primary tumor in the extremities rather than in the lungs without focusing on the imaging findings of these rare lesions (2) (3) (4) . We report a case of PPSS that eventually metastasized to the heart in a 17-year-old female.
Case Presentation
A 17-year-old female presented with dull pain in the left upper chest alternating with brief periods of chest discomfort lasting a few months. She and her parents were nonsmokers with no history of radiation or chemical exposure. She had no serious medical or surgical history and grew up in normal residential and social environments. She had no shortness of breath or cough. There was no history of weight loss, fever, or night sweats. Her vital signs and physical examination were unremarkable. All laboratory data including blood tests, standard biochemical tests, and urinalysis were within normal limits.
Chest radiographs ( Figure 1A and B) revealed a welldefined round mass in the left upper hemithorax. The mass was at an obtuse angle to the chest wall and was approximately 8 cm long. There was no other abnormality in the lung parenchyma or bony thorax.
Chest CT ( Figure 1C -E) confirmed a well-defined ovalshaped mass with heterogeneous enhancement in the left upper hemithorax abutting the pleura. In the pre-contrast image, the lesion showed homogeneous soft tissue attenuation and a lack of calcification, but a small amount of high-attenuation fluid was present in the left pleural space, suggestive of hemothorax. After contrast enhancement, the mass showed heterogeneous enhancement, with attenuation similar to that of the back muscles, and contained subtle low densities suggestive of necrosis or hemorrhage. There was no evidence of adjacent bone destruction or chest wall invasion. The mediastinal and hilar lymph nodes were not enlarged. In the scanned portion of the abdomen, there were no masses, lymphadenopathy, or ascites.
F-18
fluorodeoxyglucose positron emission tomography-CT (18F FDG PET/CT) revealed increased FDG uptake in the mass, with a maximum standardized uptake value of 31.7 ( Figure 1F ).
From these imaging findings, the diagnoses of a localized fibrous tumor of the pleura, malignant mesothelioma, metastatic pleural malignancy, and rare primary pulmonary sarcoma (e.g., pleuropulmonary synovial sarcoma, fibrosarcoma, leimyosarcoma, sarcomatoid carcinoma, malignant nerve sheath tumor, hemangiopericytoma, and malignant fibrous histiocytoma) were considered. These diagnoses were based on the tumor's appearance as a sharply marginated, heterogeneously enhanced mass with low attenuation foci and no involvement of the bone or calcifications. CT-guided core needle biopsy of the mass yielded two samples of yellowish gelatinous material. Microscopic examination showed relatively uniform spindle-shaped cells with occasional mitoses arranged in tight fascicles. The tumor cells were immunoreactive to vimentin and CD99 and were focally positive for epithelial membrane antigen (EMA), suggesting a monophasic synovial sarcoma. Medical and surgical oncologists agreed to treat the tumor with surgical resection and to initiate a combination chemotherapy regimen consisting of five cycles of vincristine, doxorubicin, and cyclophosphamide, alternating with four cycles of ifosfamide and etoposide. A thoracotomy was performed, and the mass was found to arise from the visceral pleura and to adhere to the left first to third intercostal spaces, with invasion into the left first intercostal muscle with adjacent hemothorax. The surgical specimen consisted of an 8.0 × 6.5 × 5.5 cm wellcircumscribed but unencapsulated tumor. The tumor was whitish-yellow, soft, and fleshy with cystic degenerative changes and hemorrhage. There was no calcification in the tumor. Histologically, the tumor was composed of densely 2
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packed, cellular sheets of spindle cells, and some of the tumor cells were arranged in intersecting fascicles in a herringbone pattern, suggesting fibrosarcoma-like changes ( Figure 1G -H). Loose and hypocellular focal areas were found at the periphery of the tumor. The tumor cells were relatively uniform with ovoid nuclei, scant cytoplasm, and occasional mitotic figures. Immunohistochemical staining revealed immunoreactivity of the tumor cells to cytokeratin, EMA, and CD99 but not to CD34 or desmin ( Figure 1I -J). A final diagnosis of a monophasic synovial sarcoma from the visceral pleura was made based on the histological and immunohistochemical findings. She was discharged after surgical resection without complications, after which she underwent adjuvant chemotherapy and radiotherapy.
The patient remained stable for 28 months until followup contrast-enhanced chest CT revealed a 1.6 cm low attenuation nodule with poor enhancement in the left pericardial area and a small amount of left pericardial and pleural fluid (Figure 2A ). Subsequent 18F FDG PET/CT showed slightly increased FDG uptake in the developing nodule with suspected metastasis. Five months after discovery, follow up contrast-enhanced chest CT demonstrated a wellcircumscribed polycyclic marginated mass with heterogeneous enhancement in the left pericardial region that had enlarged from 1.6 cm to 5.1 cm ( Figure 2B ). Although MRI is the most accurate technique for demonstrating cardiac mass, oncologists found the following MRI might be ineffective for choosing further treatment for the pericardial mass due to high cost. They had no choice but to do surgery for the mass whether to perform MRI or not. Additionally, CT also provided proper information for ongoing surgery. Therefore, they agreed to operate surgical resection to treat pericardial mass without obtaining cardiac MRI.
A second mass resection was performed. The tumor specimen was a 6.0 × 5.0 × 2.0 cm well-circumscribed, whitish-yellowish, fleshy to rubbery mass with zones of necrosis and hemorrhage. The tumor was lateral to the left ventricular wall with invasion into the pericardium, myoendocardium, and endocardium of the left ventricle. Microscopically, the tumor contained tight clusters and fascicles of spindle cells with scant cytoplasm, identical to the PPSS, confirming a metastatic synovial sarcoma with left pericardial, myoendocardial, and endocardial involvement.
After metastatectomy, the patient received adjuvant chemotherapy and radiotherapy. The patient's postoperative period was complicated by recurrent pneumonia. Next, hematogenous metastases were detected in the liver, breast, and pleura. The patient died from sepsis 37 months after the initial diagnosis.
Discussion
PPSS is a rare mesenchymal spindle cell malignancy representing a type of pulmonary sarcoma that comprises 0.1% -0.5% of all primary lung malignancies. Typically, it arises from the chest wall, lung parenchyma, pleura, or mediastinum, but rarely at the level of the bronchial tree, and during the fifth decade of the patient's life (1). There is no significant gender difference in incidence (5). The prognosis for patients with PPSS remains uncertain but is usually poor. The 5-year survival rate varies from 36% to 76% (6) .
A small but increasing number of cases of PPSS have been reported over the past decades (5), but very few of these cases have involved cardiac metastasis. Cardiac metastasis from soft tissue sarcomas varies from 3.5% to 35%, with only two cases of metastatic synovial sarcoma of the heart reported: one involving the right ventricle and the other the left ventricle. Both of those cases had a primary tumor in the extremities but not in the lung without focusing on the imaging findings of these rare lesions (2-4). Additionally, a literature review of soft tissue sarcomas included only 105 cases of cardiac metastasis. In that review, the predominant histological type was leiomyosarcoma (22%) followed by rhabdomyosarcoma (19%), and liposarcoma (9%); 27% of the cases were unspecified. That report suggested that the clinical manifestation of cardiac metastasis can be subtle, as one-third presented with congestive cardiac failure, which led to other complications such as embolism, tumor thrombus, cardiac tamponade, and arrhythmia (2). In our case, the patient was initially asymptomatic except for dull chest pains with only pericardial effusion on follow-up chest CT. Symptoms frequently associated with these tumors are chest pain, dyspnea, and cough; up to 40% of patients are asymptomatic (7) .
The radiological features of PPSS are summarized as follows: chest radiographs typically demonstrate a welldefined pleural-based or parenchymal mass-like lesion occasionally associated with ipsilateral pleural effusion. Generally, the contralateral lung is not involved. CT and magnetic resonance imaging (MRI) are relatively useful tools for evaluating PPSS, although the findings are nonspecific. The most common CT finding of PPSS is a well-defined, heterogeneously enhancing mass often with combined ipsilateral pleural effusion. The inner low-density area often contains necrosis, hemorrhage, or fibrous components. Associated lymphadenopathy as well as calcifications, cortical bone destruction, or tumor infiltration of the chest wall and musculature are infrequent. MRI is useful for assessing the extent of the tumor. On MRI, PPSS often exhibits heterogeneous high signal intensity on T2-weighted images and iso-or low signal intensity on T1-weighted images. After administering gadolinium, PPSS presents as a The prognosis of PPSS remains uncertain but is usually poor. The 5-year survival rate varies from 36% to 76% depending on the patient's age, tumor size, and tumor resectability (6) . There is no recommended treatment for PPSS, but the mainstay of treatment for all soft tissue sarcomas is surgical resection. Aggressive surgery can reduce the tumor size before or after chemotherapy, and complete surgical excision seems to improve the survival of patients with PPSS. Radiation therapy can also be used to treat PPSS (1). Combination chemotherapy consisting of doxorubicin and ifosfamide has been associated with higher rates of survival in patients with synovial sarcoma (6) .
In summary, PPSS is a very rare, aggressive malignancy that must be considered in the differential diagnosis of lung and pleural malignancies. The imaging findings of PPSS are nonspecific, and PPSS is difficult to confirm based on imaging; detailed immunohistochemical staining is required for definitive diagnosis. PPSS with cardiac metastasis is also extremely rare, and only two such cases have been reported. However, cardiac metastasis of PPSS can lead to immediate or delayed death; therefore, early detection and appropriate management are very important to extend survival. 
